Additionally, the cut-off for c-MYC ‘positivity’, selected based on parameters for HER2 FISH testing in breast cancer, may not have been set sufficiently high enough to overcome this therapeutic hurdle. The gene discussed is ERBB2; the disease is breast cancer.